Jefferies (NYSE:JEF) analyst David Steinberg maintained a Buy rating on Zoetis (NYSE:ZTS) on Thursday, setting a price target of $235, which is approximately 15.89% above the present share price of $202.77.
Steinberg expects Zoetis to post earnings per share (EPS) of $1.08 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Zoetis, with an average price target of $229.71.
The analysts price targets range from a high of $238 to a low of $220.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $1.95 billion and a net profit of $724 million. The company's market cap is $96.1 billion.
According to TipRanks.com, Jefferies analyst David Steinberg is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.1% and a 49.55% success rate.
Founded in 1952, New Jersey-based Zoetis, Inc. is the world's largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.